NASDAQ:XBIO

Xenetic Biosciences Q3 2025 Earnings Results & Report

Xenetic Biosciences logo
$1.40 -0.14 (-9.09%)
Closing price 11/20/2026 03:47 PM Eastern
Extended Trading
$1.46 +0.06 (+3.93%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Xenetic Biosciences beat analyst earnings expectations in its Q3 2025 results, released November 12, 2025. The company reported EPS of -$0.33 versus the -$0.49 consensus estimate, while revenue was $1.03 million.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call
8:30 AM ET

Xenetic Biosciences EPS Results

Actual EPS
-$0.33
Consensus EPS
-$0.49
Beat/Miss
Beat by +$0.16
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Xenetic Biosciences Revenue Results

Actual Revenue
$1.03 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Xenetic Biosciences Q3 2025 Earnings FAQ

Xenetic Biosciences (NASDAQ:XBIO) reported earnings of -$0.33 per share for Q3 2025, beating the consensus estimate of -$0.49. The report was announced on Wednesday, November 12, 2025.

Xenetic Biosciences reported revenue of $1.03 million for Q3 2025.

Xenetic Biosciences Earnings Headlines

Contrasting Xenetic Biosciences (XBIO) and Its Peers
Worse than socialism
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
See More Xenetic Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Xenetic Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xenetic Biosciences and other key companies, straight to your email.

About Xenetic Biosciences

Xenetic Biosciences (NASDAQ:XBIO) is a biotechnology company focused on developing immuno-oncology treatments. Its XCART platform is designed to create personalized CAR T-cell therapies that recognize tumor-specific antigens on B-cell lymphomas, with the goal of targeting cancer cells while limiting effects on healthy cells.

The company’s earlier work included PolyXen, a drug-delivery platform based on polysialic acid that was designed to extend the time biologic medicines remain in the body. Xenetic’s current stated focus is advancing its XCART technology and related product candidates.

View Xenetic Biosciences Profile